Cellectar Biosciences Inc (CLRB)

[Crusader]

This seals the credibility of today's PR:

12-6-17:

"...In addition to the CLR 131 infusion(s), MM patients will receive 40 mg oral dexamethasone weekly for up to 12 weeks. Efficacy responses will be determined by the latest International Multiple Myeloma Working Group criteria. Efficacy for all lymphoma patients will be determined according to Lugano criteria. Cellectar will receive approximately $2 million in a non-dilutive grant from the National Cancer Institute to help fund the trial. More information about the trial, including eligibility requirements, can be found at www.clinicaltrials.gov, reference NCT02952508."

THOSE 10% SHORTS ARE GOING TO HAVE TO COVER AFTER THEY RAKE IN YOUR MONEY A FEW MORE TIMES. THIS STOCK IS THE REAL DEAL FOR SO MANY SUFFERING TYPES OF CANCER PATIENTS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

They are the ones who count in this happy ending story.